MedTrace Logo

Peanuts Second Meal Glycemic Response

NCT01413126 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-08-10

No results posted yet for this study

Summary

Nut consumption is associated with reduced risk of Type 2 diabetes. The aim of this study was to assess the effects of peanut (whole or peanut butter) to breakfast meals on glycemic, insulinemic and selected gut hormone responses, appetite, and food intake over two consecutive meals in obese women with high Type 2 diabetes risk. Fifteen women participated in a randomized crossover trial where 42.5g of whole peanuts (P), peanut butter (PB), or no peanuts (control-C) were added to a 75g available carbohydrate-matched breakfast meal. Postprandial concentrations of blood glucose, insulin, non-esterified free fatty acids (NEFA), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), appetitive sensations and food intake were assessed after breakfast treatments and a standard lunch (75g available carbohydrate).

Conditions

Interventions

DIETARY_SUPPLEMENT

Whole peanuts without skins, Peanut butter, or no peanuts (control)

In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.

Sponsors & Collaborators

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

    collaborator OTHER_GOV

  • Fundação de Amparo à Pesquisa do estado de Minas Gerais

    collaborator OTHER

  • United States Agency for International Development (USAID)

    collaborator FED

  • Federal University of Vicosa

    lead OTHER

Principal Investigators

  • Caio EG Reis, PhD Student · University of Brasília, Brazil

  • Daniela N Ribeiro, M.Sc. · Federal University of Viçosa, Brazil

  • Neuza MB Costa, Ph.D. · Federal University of Espírito Santo, Brazil

  • Josefina Bressan, Ph.D. · Federal University of Viçosa, Brazil

  • Rita CG Alfenas, Ph.D. · Federal University of Viçosa, Brazil

  • Richard D Mattes, Ph.D. · Purdue University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-09-30
Completion
2011-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413126 on ClinicalTrials.gov